Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled ...

Regeneron recently secured approval for Dupixent in treating Chronic Obstructive Pulmonary Disease (COPD) in the European Union, with a pending approval decision in the United States expected in ...

Verona Pharma PLC (VRNA) reports significant sales growth for Ohtuvayre, but faces increased expenses and competition in the COPD market.

Regeneron recently secured approval for Dupixent in treating Chronic Obstructive Pulmonary Disease (COPD) in the European Union, with a pending approval decision in the United States expected in the ...

Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023Third quarter 2024 Dupixent® global net sales(recorded by ...

In September, the FDA and Chinese regulators both approved Dupixent for patients with uncontrolled COPD and an eosinophilic phenotype. These approvals, along with the approval in Europe in June ...

Regeneron is actively pursuing additional indications for Dupixent, with a particular focus on chronic obstructive pulmonary disease (COPD). The drug recently received approval for COPD treatment in ...

Many new medicines that work directly on the body’s immune system are being studied for the treatment of COPD. In 2024, Dupixent became the first of these medicines to be approved for COPD.

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

Reports Q3 revenue $3.72B, consensus $3.67B. “Regeneron (REGN) had a strong third quarter marked by 11% revenue growth. We continued to ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...